Unilateral RLB affects both eyes

Article

Laser burn to the retina of a single eye can compromise the immune privilege of the fellow eye.

Laser burn to the retina of a single eye can compromise the immune privilege of the fellow eye, concluded a study published in the February issue of the American Journal of Pathology.

Joan Stein-Streilein of Schepens Eye Research Institute, US and colleagues inflicted retinal laser burns (RLBs) on a single eye of 15 mice and injected both eyes with the antigen, Ovalbumin. Control mice, that had not been exposed to the laser burn, were also injected with Ovalbumin.

The immune privilege of both eyes was damaged six hours after RLB. This damage endured for up to 56 days. The control mice, however, experienced no inflammation, showing that the immune privilege of their eyes was not compromised. The team now intends to study the interactions between eyes to understand the novel mechanisms that allow for communication between the injured and non-injured eye.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.